Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

While programmed cell death 1 (PD-1) inhibitors have shown clear anti-tumor efficacy in several solid tumors, prior results in men with metastatic castration resistant prostate cancer (mCRPC) showed no evidence of activity. Here we report unexpected antitumor activity seen in mCRPC patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Graff, Julie N., Alumkal, Joshi J., Drake, Charles G., Thomas, George V., Redmond, William L., Farhad, Mohammad, Cetnar, Jeremy P., Ey, Frederick S., Bergan, Raymond C., Slottke, Rachel, Beer, Tomasz M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper: Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288150/
https://www.ncbi.nlm.nih.gov/pubmed/27429197
http://dx.doi.org/10.18632/oncotarget.10547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288150/
https://www.ncbi.nlm.nih.gov/pubmed/27429197
http://dx.doi.org/10.18632/oncotarget.10547

Ejemplares similares